Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) [Trend Analysis] swings enthusiastically in regular trading session, it a loss of -0.79% to close at $41.24. AlnylamPharma (ALNY) announced new positive results from its ongoing Phase 2 open-label extension study with fitusiran in patients with hemophilia A or B without inhibitors.
New clinical data showed that once-monthly subcutaneous administration of fitusiran achieved consistent lowering of AT and increases in thrombin generation, resulting in a median estimated annualized bleeding rate (ABR) of 1.0 in patients with hemophilia A or B without inhibitors. In addition, fitusiran was generally well tolerated, with no thromboembolic events or laboratory evidence of pathologic clot formation through the data cut-off date.
The Phase 2 OLE study results as of the data cut-off date of October 6, 2016 included 16 hemophilia A or B patients without inhibitors. Both dose levels achieved mean AT lowering of approximately 80 percent and mean increases in thrombin generation levels approaching the lower end of the range observed in normal healthy individuals in Part A of the Phase 1 study.
In an exploratory post hoc analysis of bleed events, fitusiran achieved a median overall ABR of 1.0, over a median observation period of 5.7 months, compared to a median pre-study ABR of 4.0. In the study, 8 out of 16 patients (50 percent) reported zero bleeds and 11 out of 16 patients (69 percent) experienced zero spontaneous bleeds. Moving forward to saw long-term intention, the experts calculate Return on Investment of -23.40%. The stock is going forward its fifty-two week low with 31.42% and lagging behind from its 52-week high price with -62.20%. ALNY last month stock price volatility remained 7.19%.
Ocwen Financial Corporation (NYSE:OCN) [Trend Analysis] knocking active thrust in leading trading session, shares a gain of 2.18% to 5.16 with around 1.35 Million shares have changed hands in this session. Ocwen Financial Corporation, (OCN) released that as of 5:00 p.m., New York City time, on December 2, 2016, which was the Expiration Date for the previously announced Exchange Offer by its subsidiary Ocwen Loan Servicing, LLC, $346.9 million aggregate principal amount (or 99.1%) of Ocwen’s 6.625% Senior Notes due 2019 (the “Existing Notes”) had been tendered in the Exchange Offer.
The settlement date for the Exchange Offer is expected to occur promptly following the Expiration Date, subject to the satisfaction or waiver of the conditions to the Exchange Offer. The Exchange Offer is purely a debt-for-debt exchange offer and none of OLS, Ocwen or any of their subsidiaries will receive any cash proceeds from the transaction. The stock is going forward its fifty-two week low with 300.00% and lagging behind from its 52-week high price with -32.37%.
Similar, the positive performance for the quarter recorded as 54.95% and for the year was -17.83%, while the YTD performance remained at -25.97%. OCN has Average True Range for 14 days of 0.23.